Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rare Form: GSK, NEA Back Orphan Disease Venture Fund

This article was originally published in Start Up

Executive Summary

A new fund offering access to European translational research focused on rare diseases has high-profile backers and reunites key players in the successful Prosensa IPO.

You may also be interested in...



Prosensa Debuts On The Nasdaq Hours After Getting Breakthrough Designation For Lead Compound

The Dutch biotech raised $78 million in an initial public offering, peaking investors’ interest with a breakthrough designation for its lead drug candidate, partnered with GSK.

Early Stage Biotech IPOs Join Late-stage Plays In Appealing to Investors

With Epizyme as a top performing biotech IPO and bluebird bio primed to go out soon, investor appetite would seem whetted for early stage biotechs on the public market. With improving overall IPO performance, these returns could again become meaningful for more than a few life science VCs.

Orphan Drugs To Make Up 16% Of Rx Market By 2018, Says Evaluate Pharma

The health care consultancy released a report that shows the rapid growth of the orphan drug sector as companies take advantage of incentives. Orphan oncologic drugs dominate the market, and Novartis is slated to lead in orphan sales by 2018.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel